AbbVie, Inc. (ABBV)
276.47
+4.05
(+1.49%)
USD |
NYSE |
Oct 09, 16:00
276.47
0.00 (0.00%)
After-Hours: 20:00
AbbVie Free Cash Flow (Quarterly) : 3.114B for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.114B |
| March 31, 2026 | 3.564B |
| December 31, 2025 | 4.889B |
| September 30, 2025 | 6.643B |
| June 30, 2025 | 4.884B |
| March 31, 2025 | 1.40B |
| December 31, 2024 | 6.757B |
| September 30, 2024 | 5.198B |
| June 30, 2024 | 2.03B |
| March 31, 2024 | 3.847B |
| December 31, 2023 | 4.51B |
| September 30, 2023 | 7.355B |
| June 30, 2023 | 6.141B |
| March 31, 2023 | 4.018B |
| December 31, 2022 | 7.215B |
| September 30, 2022 | 7.425B |
| June 30, 2022 | 4.862B |
| March 31, 2022 | 4.746B |
| December 31, 2021 | 4.888B |
| September 30, 2021 | 7.718B |
| June 30, 2021 | 4.695B |
| March 31, 2021 | 4.689B |
| December 31, 2020 | 3.375B |
| September 30, 2020 | 5.613B |
| June 30, 2020 | 2.912B |
| Date | Value |
|---|---|
| March 31, 2020 | 3.69B |
| December 31, 2019 | 3.112B |
| September 30, 2019 | 4.572B |
| June 30, 2019 | 2.178B |
| March 31, 2019 | 2.91B |
| December 31, 2018 | 3.269B |
| September 30, 2018 | 4.242B |
| June 30, 2018 | 2.752B |
| March 31, 2018 | 2.526B |
| December 31, 2017 | 2.402B |
| September 30, 2017 | 3.145B |
| June 30, 2017 | 1.877B |
| March 31, 2017 | 2.007B |
| December 31, 2016 | 1.427B |
| September 30, 2016 | 1.341B |
| June 30, 2016 | 1.787B |
| March 31, 2016 | 2.007B |
| December 31, 2015 | 1.818B |
| September 30, 2015 | 2.028B |
| June 30, 2015 | 1.717B |
| March 31, 2015 | 1.44B |
| December 31, 2014 | -731.00M |
| September 30, 2014 | 1.606B |
| June 30, 2014 | 1.575B |
| March 31, 2014 | 487.00M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Biogen, Inc. | 308.00M |
| Gilead Sciences, Inc. | 3.433B |
| Amgen, Inc. | 3.489B |
| REGENXBIO, Inc. | -63.00M |
| Abbott Laboratories | 1.991B |